Troy Wilson, Kura CEO
November 24, 2021 07:01 AM ESTUpdated 10:30 AM
R&D
FDA+

FDA hits the red light on an ear­ly-stage AML study af­ter a pa­tient dies

John Carroll

Editor & Founder

Max Gelman

Senior Editor

The FDA has slapped a clin­i­cal hold on the ear­ly-stage pro­gram for one of Ku­ra On­col­o­gy’s can­cer drugs fol­low­ing a pa­tient’s death in a clin­i­cal …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

A service from the Financial Times